Cornish businessman scoops Topra award

Jonathan Trethowan wins Inspiration category

Jonathan Trethowan, director of regulatory affairs company Trac Services, based in Camborne, Cornwall, UK, has taken top honours in the Inspiration category at the Topra Symposium (the organisation representing regulatory affairs professionals).

A panel of five judges awarded Trethowan the honour at the awards, which recognise excellence within the industry, after he was nominated by Trac’s regulatory affairs executive, Lisa Pascoe.

Trethowan set up the company with his wife Sarah in 2001 and has seen it grow to work with UK and European pharmaceutical companies, ensuring that they are in compliance with the latest regulations concerned with the manufacture and marketing of medicines.

‘I am absolutely delighted to have won the Inspiration Award – it is a fantastic honour and to be honest I was thrilled just to be nominated,’ said Trethowan.

Pascoe added: ‘Over the past five years Jonathan has developed an excellent in-house training programme that has helped coach and support myself and six other graduates to become experienced regulatory professionals in our own right.

‘In addition, he also participates in a TOPRA working party that is identifying future approaches to professional development; I think his involvement at TRAC and within the industry as a whole shows his passion and commitment.’

You may also like

Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Regulatory

American Chemistry Council's statement to Trump: make chemistry in America again

The Council has released a statement ahead of the President's State of the Union Address, asking for policies that unlock domestic production and address unfair foreign practices
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Regulatory

NICE approves Opzelura cream as first UK treatment for non-segmental vitiligo

Incyte Biosciences UK has secured NICE approval for Opzelura (ruxolitinib) cream, granting eligible NHS patients with non-segmental vitiligo access to the first and only approved therapy in England shown to support facial re-pigmentation
Regulatory

CDA-AMC rejects Leqembi reimbursement despite Health Canada approval

After expressing disappointment about a separate insomnia ruling, Eisai has criticised a draft decision by Canada's drug agency not to recommend public reimbursement of Leqembi for early Alzheimer's disease
Regulatory

Shield Therapeutics’ ACCRUFeR becomes first FDA-approved oral iron for children 10+

The FDA's approval for ACCRUFeR (ferric maltol) to treat iron deficiency in children aged 10 and older makes it the first and only prescription oral iron therapy specifically approved for this pediatric population
Regulatory

Hansa Biopharma’s imlifidase BLA accepted for FDA review

The US Food and Drug Administration has accepted the company's Biologics License Application for imlifidase, a novel IgG-cleaving enzyme designed to enable HLA-incompatible kidney transplantation
Subscribe now